Image Description
Intraductal Papillary Mucinous Neoplasm (IPMN) of Pancreas - Treatment & Prognosis: Most IPMNs are treated with complete pancreatoduodenectomy; however, if the lesion is more distal in the body or tail of the pancreas, a distal pancreatoduodenectomy may be performed.
Following surgical resection, IPMNs without invasive carcinoma have a good prognosis with a 5-year survival of 100% for low-grade and 85-90% for high-grade IPMNs (shown here).
If IPMN is associated with invasive carcinoma, the 5-yr survival rate ranges from 36% to 90% depending upon the histologic type and stage of the carcinoma. Patients with colloid carcinoma have a 5-year survival rate of 55% which is better than that with ductal adenocarcinoma. The prognosis is also excellent for cases with microinvasive focus (< 5 mm in size). Branch duct-IPMNs are less likely to harbor an invasive carcinoma and they have a better outcome than main duct-IPMN.
Following surgical resection, IPMNs without invasive carcinoma have a good prognosis with a 5-year survival of 100% for low-grade and 85-90% for high-grade IPMNs (shown here).
If IPMN is associated with invasive carcinoma, the 5-yr survival rate ranges from 36% to 90% depending upon the histologic type and stage of the carcinoma. Patients with colloid carcinoma have a 5-year survival rate of 55% which is better than that with ductal adenocarcinoma. The prognosis is also excellent for cases with microinvasive focus (< 5 mm in size). Branch duct-IPMNs are less likely to harbor an invasive carcinoma and they have a better outcome than main duct-IPMN.